Head-Fixed Mice Learn to Self-Administer Drugs, Opening a New Window on Addiction

Drug addiction research has long faced a stubborn methodological dilemma. To understand why people take drugs despite devastating consequences, scientists need animal models that capture the voluntary, goal-directed nature of drug seeking and drug taking. Yet the most powerful modern tools for watching the brain in action—two-photon calcium imaging, optogenetic manipulation of identified cells, and high-resolution behavioral tracking—work best when the animal’s head is held perfectly still. A newly published protocol in Nature Protocols by Kenichiro Negishi, Ginevra D’Ottavio, and Yavin Shaham of the Behavioral Neuroscience Branch at the National Institute on Drug Abuse’s Intramural Research Program in Baltimore now brings these two worlds together, providing detailed instructions for assembling the hardware and implementing intravenous drug self-administration in head-fixed mice.

The significance of self-administration models in addiction neuroscience is difficult to overstate. Unlike passive drug exposure experiments, in which the investigator simply injects an animal with a drug and observes the consequences, self-administration paradigms allow the animal itself to control when and how much drug it receives, typically by pressing a lever or poking its nose into a port. This voluntary element matters enormously. It allows investigators to dissociate the behavioral and neural mechanisms that motivate drug seeking and taking from the pharmacological effects of drug exposure itself, a distinction that lies at the heart of modern addiction research. Compulsive drug taking, relapse after abstinence, and the escalation of intake over time are all phenomena that only emerge when the animal has agency over its own drug consumption.

The intellectual lineage of this approach stretches back more than eight decades. As the authors note in their News and Views commentary accompanying the protocol, the earliest demonstrations that animals will work to obtain drugs appeared in the comparative psychology literature of 1940, when Spragg reported that chimpanzees would manipulate mechanisms to gain access to morphine. In the mid-1950s, Headlee, Coppock, and Hichols described intravenous morphine administration procedures in the Journal of Pharmaceutical Sciences, laying groundwork for controlled delivery of drugs into the bloodstream of laboratory animals. These early efforts culminated in a landmark 1962 study by James Weeks, published in Science, which established the operant intravenous drug self-administration procedure in rats—a technique that remains the workhorse of preclinical addiction research to this day.

The field built rapidly on that foundation. Thompson and Schuster demonstrated in 1964 that the principles of operant conditioning could be applied to morphine self-administration, and Risner and Jones extended the approach in 1975 to compare the reinforcing effects of different drugs. By 1991, Carney and colleagues were using self-administration procedures to study stimulant pharmacology, and the paradigm had become a standard screen for the abuse liability of novel compounds. A 2020 review by Venniro, Banks, Heilig, Epstein, and Shaham in Nature Reviews Neuroscience synthesized how decades of self-administration research had refined the field’s understanding of the neural circuits of drug reward, relapse, and the economic and social factors that influence drug taking. The historical arc is clear: each generation of methodological refinement has allowed sharper questions to be asked about why drugs are so compelling.

What the new protocol adds is the head-fixed dimension. In a conventional self-administration chamber, a mouse moves freely, presses levers, and receives intravenous infusions through a catheter implanted in its jugular vein. This arrangement is behaviorally rich but experimentally constrained. The animal’s head moves unpredictably, which degrades optical recordings, complicates the delivery of precisely timed sensory stimuli, and makes it nearly impossible to hold a microscope objective or a stimulus display in a fixed relationship to the animal’s eyes and whiskers. Head fixation solves these problems. With the skull rigidly stabilized, researchers can perform stable two-photon imaging of the same population of neurons across many sessions, deliver visual or auditory cues with millisecond precision, and apply optogenetic or pharmacological manipulations to genetically identified circuits while the animal is actively working for drug.

Combining head fixation with intravenous self-administration, however, is far from trivial, and this is precisely where the protocol makes its contribution. The authors provide step-by-step instructions for assembling the necessary hardware, integrating the head-fixation apparatus with the operant response devices and the infusion system that delivers drug through the implanted catheter. The technical challenges are considerable: the catheter must remain patent across repeated sessions while the animal is restrained; the operant manipulandum must be positioned so that a head-fixed mouse can respond comfortably; and the infusion line must be routed so that drug delivery is synchronized with the animal’s responses without introducing movement artifacts or leaks. By documenting these details, the protocol lowers the barrier for laboratories that want to adopt the technique without months of trial and error.

The timing of this methodological advance reflects a broader convergence in the field. A companion protocol by Doncheck and colleagues, also published in Nature Protocols in 2026 and cited in the commentary, indicates that head-fixed drug self-administration is emerging as a coherent methodological platform rather than the idiosyncratic setup of a single laboratory. Meanwhile, recent work published in Neuron in 2024 by Paniccia and colleagues demonstrated the scientific payoff of head-fixed approaches, and a 2021 study by Vollmer and colleagues in Frontiers in Behavioral Neuroscience explored related territory in freely moving animals. Together, these publications sketch a research landscape in which the voluntary taking of intravenous drugs can finally be observed with the full arsenal of modern circuit neuroscience.

For researchers weighing whether to adopt the technique, the trade-offs are worth understanding. Freely moving self-administration preserves the naturalistic ethology of drug seeking—the animal navigates its environment, approaches the drug source, and integrates spatial and contextual cues into its behavior. Head-fixed preparations sacrifice some of that naturalism in exchange for experimental control and optical stability. The authors’ framing suggests that the two approaches should be viewed as complementary rather than competing: freely moving studies establish the validity of a behavioral phenomenon, while head-fixed preparations dissect its circuit-level mechanisms with cellular precision. A protocol that makes the head-fixed variant accessible and reproducible therefore expands the toolkit available to the field rather than replacing the established one.

The potential applications span the major questions of addiction neuroscience. With a head-fixed mouse pressing a port for intravenous cocaine, opioid, or other drug infusions, investigators could track how neurons in the prefrontal cortex, nucleus accumbens, dorsal striatum, or amygdala change their activity as drug seeking becomes habitual, as intake escalates, or as cues that predict drug availability come to drive behavior. They could test whether manipulating specific projections alters the propensity to seek drug, and they could do so across many consecutive sessions with imaging planes held perfectly stable. Because the animals are mice rather than rats, the full power of mouse genetics—cell-type-specific reporters, conditional knockouts, and activity-dependent labeling—becomes available to self-administration research in ways that were previously cumbersome.

As with any methodological innovation, the ultimate test will be how widely the technique is adopted and what it reveals. The authors declare no competing interests, and the protocol, published as a U.S. Government work, is accompanied by supplementary information including an additional figure and references to support implementation. For a field that has spent more than sixty years refining the operant self-administration paradigm since Weeks first described it in Science, the arrival of a validated head-fixed variant marks a genuine expansion of the frontier. If it delivers on its promise, the coming years should see drug self-administration experiments in which every lever press is paired with a window into the living brain—bringing addiction neuroscience closer to the mechanistic depth that the problem of addiction demands.

Subject of Research: A protocol for performing intravenous drug self-administration in head-fixed mice to study the neural mechanisms of addiction.

Article Title: Head-fixed intravenous drug self-administration: a new frontier in addiction neuroscience

Article References: Negishi, K., D’Ottavio, G., & Shaham, Y. (2026). Head-fixed intravenous drug self-administration: a new frontier in addiction neuroscience. Nature Protocols. https://doi.org/10.1038/s41596-026-01438-7

Image Credits: AI Generated

DOI: 10.1038/s41596-026-01438-7

Keywords: addiction neuroscience, drug self-administration, head-fixed mice, intravenous drug delivery, Nature Protocols, behavioral neuroscience, two-photon imaging, operant conditioning, drug reward, relapse, NIDA, mouse models